替雷利珠單抗治療晚期非小細胞肺癌患者的真實世界研究

AReal-worldStudyofTislelizumabinthe TreatmentofPatients with Advanced Non-small Cell Lung Cancer

HANHan，CHEN Yuchen，LIU Yang，RENFangfang，WANGXiyong （Oncology Department，Suzhou Hospitalof Anhui Medical University，Suzhou 234ooo，Anhui，China）

Abstract：Oeiveecndefbiatofdalllungl MethodsFromJanuaryO2OtoOctober2O23，patientswithadvancedNSCLCtreatedwithtislelzumabinSuzhouHospitalofAnhuiMedical UniverstyweredsiliicalacedsftisldKaaeerddfor survivalanalydCseoodlsdfelsulAotfatiseudn PFS was 5.43（95%CI 3.84-7.03）months，the medianOSwas12.17（95%CE7.72-16.62）months，andtheORRand DCR were 3 6 . 8 4 % and 6 6 . 3 2 % ， respectively.Kaplan-Meier univariate analysis showed that metastasis siteand ECOG score were related to PFS （ P<0 . 0 5 ） ，while metastasis site，ECOG score and treatment line number were related to OS（ .Multivariate analysis showed that intrapulmonary metastasis，distant metastasis，ECOG scoreandumberoftreamentlineswereindependentinfuencingfacorsofandintrapulmonarymelastasisECOGscoreadberf treatmentneepdtcorOeytlealdee reactionsignallsdldnli patients with advanced NSCLC.

Keyods：eballluttOallal free survival

國家癌癥中心數(shù)據(jù)顯示[1，肺癌在我國惡性腫瘤中的發(fā)病率和死亡率均居于首位，給人們帶來沉重負擔。（剩余9630字）